MX2014012376A - Metodo para tratar hiperucemia en pacientes con gota usando halofenato o acido halofenico y un agente anti - inflamatorio. - Google Patents

Metodo para tratar hiperucemia en pacientes con gota usando halofenato o acido halofenico y un agente anti - inflamatorio.

Info

Publication number
MX2014012376A
MX2014012376A MX2014012376A MX2014012376A MX2014012376A MX 2014012376 A MX2014012376 A MX 2014012376A MX 2014012376 A MX2014012376 A MX 2014012376A MX 2014012376 A MX2014012376 A MX 2014012376A MX 2014012376 A MX2014012376 A MX 2014012376A
Authority
MX
Mexico
Prior art keywords
day
colchicine
therapeutic agent
halofenate
subject
Prior art date
Application number
MX2014012376A
Other languages
English (en)
Spanish (es)
Inventor
Brian Edward Lavan
Gopal Chandra Saha
Brian K Roberts
Charles A Mcwherter
Original Assignee
Cymabay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymabay Therapeutics Inc filed Critical Cymabay Therapeutics Inc
Publication of MX2014012376A publication Critical patent/MX2014012376A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2014012376A 2012-04-13 2013-04-12 Metodo para tratar hiperucemia en pacientes con gota usando halofenato o acido halofenico y un agente anti - inflamatorio. MX2014012376A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261624186P 2012-04-13 2012-04-13
PCT/US2013/036474 WO2013155478A1 (en) 2012-04-13 2013-04-12 Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent

Publications (1)

Publication Number Publication Date
MX2014012376A true MX2014012376A (es) 2015-06-05

Family

ID=49325641

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014012376A MX2014012376A (es) 2012-04-13 2013-04-12 Metodo para tratar hiperucemia en pacientes con gota usando halofenato o acido halofenico y un agente anti - inflamatorio.

Country Status (15)

Country Link
US (1) US20130274331A1 (enExample)
EP (1) EP2836209A4 (enExample)
JP (1) JP2015512948A (enExample)
KR (1) KR20150002799A (enExample)
CN (1) CN104602686A (enExample)
AU (1) AU2013245675B2 (enExample)
CA (1) CA2870014A1 (enExample)
CL (1) CL2014002728A1 (enExample)
EA (1) EA028495B1 (enExample)
HK (1) HK1204913A1 (enExample)
IL (1) IL235154A0 (enExample)
MX (1) MX2014012376A (enExample)
PH (1) PH12014502282A1 (enExample)
SG (1) SG11201406495UA (enExample)
WO (1) WO2013155478A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250138815A (ko) 2012-11-02 2025-09-22 머레이 앤 풀 엔터프라이지즈, 리미티드 콜히친 유도체의 투여를 통한 심혈관성 병태의 치료 또는 예방
SG11201508571WA (en) 2013-04-16 2015-11-27 Murray And Poole Entpr Ltd Sustained-release formulations of colchicine and methods of using same
US9907751B2 (en) 2016-03-10 2018-03-06 RxOMEG Therapeutics LLC Composition and method of use of colchicine oral liquid
US10226423B1 (en) * 2017-12-20 2019-03-12 RxOMEG Therapeutics LLC Colchicine drug-to-drug interactions
JP2023035118A (ja) * 2021-08-31 2023-03-13 国立大学法人広島大学 体液サンプリング容器

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7576131B2 (en) * 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
WO2009151695A1 (en) * 2008-03-13 2009-12-17 Wellstat Therapeutics Corporation Compounds and method for reducing uric acid
EP2249651A1 (en) * 2008-03-14 2010-11-17 Intelliherb, Llc Licorice lollipop that inhibits dental caries formation
US20100137235A1 (en) * 2008-10-15 2010-06-03 Mutual Pharmaceutical Company, Inc. Methods for Concomitant Administration of Colchicine and Macrolide Antibiotics
PL2775836T3 (pl) * 2011-11-04 2019-02-28 Cymabay Therapeutics, Inc. Sposoby leczenia zaostrzeń dny moczanowej
US9060987B2 (en) * 2011-11-04 2015-06-23 Cymabay Therapeutics, Inc. Methods for treating gout flares
EP2775835A4 (en) * 2011-11-04 2015-07-29 Metabolex Inc METHODS FOR TREATING GOUT IN GROUPS OF PATIENTS
WO2013066349A1 (en) * 2011-11-04 2013-05-10 Metabolex, Inc. Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent

Also Published As

Publication number Publication date
PH12014502282A1 (en) 2014-12-15
CL2014002728A1 (es) 2015-06-19
JP2015512948A (ja) 2015-04-30
CN104602686A (zh) 2015-05-06
EP2836209A4 (en) 2015-11-25
IL235154A0 (en) 2014-12-31
KR20150002799A (ko) 2015-01-07
AU2013245675B2 (en) 2017-02-09
EA201491870A1 (ru) 2015-03-31
CA2870014A1 (en) 2013-10-17
EA028495B1 (ru) 2017-11-30
SG11201406495UA (en) 2014-11-27
AU2013245675A1 (en) 2014-10-30
WO2013155478A1 (en) 2013-10-17
EP2836209A1 (en) 2015-02-18
HK1204913A1 (en) 2015-12-11
US20130274331A1 (en) 2013-10-17

Similar Documents

Publication Publication Date Title
US10137112B2 (en) Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
JP6008974B2 (ja) 痛風発赤の治療方法
AU2011380507B2 (en) Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
AU2013245675B2 (en) Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent
JP6047172B2 (ja) 患者部分集団における痛風の治療方法
JP6368756B2 (ja) ハロフェナートまたはハロフェン酸および第２の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法
US20130302305A1 (en) Methods for Treating Gout in Patients Subpopulations
JP6192142B2 (ja) 痛風発赤の治療方法